The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.

EASD 2018 A study found various clinical and biochemical factors that are associated with a greater risk of fast disease progression in T2DM patients.

In a retrospective cohort study, statin treatment was significantly related to a reduction in the incidence of ASCVD and in all-cause mortality in elderly T2DM patients aged <85 years, which reduced after the age of 85 years and disappeared in nonagenarians.

This EPCCS Practical Guidance Document provides a brief scientific background on the need for lipid lowering in individuals at high CV risk, and practical guidance on management of persons with dyslipidaemia in primary care, with a focus on challenges faced in clinical reality.

An explorative study compared the timepoint at which outcome curves separate among 17 statin and 7 non-statin trials. Results suggest that futility should not be declared too early in trials.

A post hoc analysis of a randomized trial showed reduced CVD risk after rosuvastatin therapy with and without candestartan/hydrochlorothiazide, regardless of the number of healthy lifestyle factors.

Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels

EPCCS 2018 A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?

A Google-driven nocebo effect may underlie statin intolerance, as countries with many websites on statin side-effects showed a higher prevalence of statin intolerance.

Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.